I'm going to say something that has made me unpopular in more than one budget meeting: the cheapest quote is usually the most expensive decision. In medical procurement, prevention over cure is not a clinical slogan. It's a cost-accounting strategy. If you've ever sat in a budget review and watched a “cost-saving” product generate a new line item for repairs, you know exactly what I mean. Trust me on this one.
I'm a procurement manager at a 220-bed regional hospital network. I've managed our medical-surgical supply budget—about $2.8 million a year—for eight years, negotiated with more than 40 vendors, and logged every order in our cost tracking system. I didn't start out with this mindset. I had to learn it from a series of expensive mistakes.
How I Started Thinking in Total Cost
When I first started buying supplies, I assumed the lowest unit price was the correct call. A budget is a number, and the fastest way to hit it is to buy the cheapest thing that meets the spec. The problem is that the spec never captures everything. It doesn't capture the extra service call, the failed outcome, or the clinician time lost to a product that fights back.
Take patient lifts. Two vendors submitted quotes for a mobile lift in Q3 2024. One quoted $4,200. The other quoted $3,100. On paper, that was a no-brainer. But I kept second-guessing: What if the cheaper unit needed more maintenance? What if the battery didn't last? I approved the cheaper one anyway. That was a mistake. I still remember those numbers.
Over three years, the cheap patient lift needed extra slings ($180 each), a service contract ($600 a year), and a replacement battery ($240). The original $3,100 quote turned into $5,080 in total. The $4,200 quote included all of that. The “savings” was a phantom. That's when I built my TCO spreadsheet. Now every major purchase gets the same treatment: list the purchase price, the consumables, the service plan, the failure rate, and the cost of a bad outcome.
We didn't have a formal total-cost review for big purchases back then. Now we do. That one policy change cut our unplanned maintenance spending by roughly 20% in the following year.
It took me three years and about 40 vendor negotiations to understand that the “best” price is context-dependent. The only defensible number is total cost over the product's useful life. A patient lift isn't “cheaper” if it breaks down more. A dental implant isn't “cheaper” if it leads to a revision. And a dressing isn't “cheaper” if it damages the skin it's supposed to protect.
Why I Changed My Mind About Mölnlycke
For years, I categorized Mölnlycke products as “premium” and moved on. The prices didn't fit my old playbook. Then a wound care nurse walked me through a case where a standard dressing removed part of a fragile patient's skin. The extra treatment days weren't in my spreadsheet, but they were in the hospital's cost. I couldn't unsee that.
I started reading the evidence. On the Molnlycke official website (I checked in January 2025), they publish clinical outcome data behind Safetac adhesive technology. The claim is simple: dressings with Safetac minimize pain and skin damage on removal. That matters because skin damage is not a side effect—it's a cost driver. One skin tear can add days to a recovery, and every day has a bed cost, a nursing cost, and a supply cost.
When I look at a dressing contract now, I ask three questions: How many dressing changes will this patient likely need? What happens to the wound bed when the dressing is removed? And what is the cost of a skin tear or a stalled wound in our population? The first answer tells me unit volume. The second and third tell me the real price. Mölnlycke's Safetac data answered those questions better than most.
The Molnlycke Health Care US official website doesn't hide behind vague marketing. It links to studies, instructions, and clinical evidence. For a procurement person, that's a huge signal. A supplier that documents outcomes is a supplier that understands downstream costs. It also makes my job easier: instead of relying on my own failure data, I can start with theirs.
Dental implant components taught me the same lesson in a different specialty. A $75 difference per implant kit looked like a win until a failed fixture turned into a revision surgery that cost 12 times that amount. Unit price is the price to buy a product. Total cost is the price to live with it. That principle doesn't change because the product comes from a different supply catalog.
Of course, not every premium product earns its premium. I've rejected plenty of high-priced items after running the numbers. But the Mölnlycke products that I currently buy under contract—dressings, gloves, drapes—earned their place because the evidence says they reduce the events I'm trying to prevent. That's the standard now.
The Counterintuitive Argument: Diagnostics Are Prevention
Here's the argument that surprised me: some prevention isn't a physical product at all. It's information. If you've ever wanted a plain-English answer to 'how does pcr work,' here it is: polymerase chain reaction makes millions of copies of a specific DNA sequence, which lets a lab detect a pathogen before it becomes an outbreak. That early detection is prevention. I know it's not a dressing or a drape, but it operates on the same principle.
I once talked to a lab director who put it bluntly: “A $50 PCR test can stop a $150,000 infection cluster.” I couldn't argue with the math. The same logic applies to surgical gloves and drapes. A barrier that prevents surgical-site contamination costs pennies compared to the treatment it avoids. That's why I started taking infection prevention products seriously—not just as a clinical choice, but as a procurement hedge.
The 'how does pcr work' question taught me something else: prevention usually costs more at the front end and less at the back end. PCR testing is not free. But neither is an outbreak. The same is true for surgical supplies. Mölnlycke's Biogel gloves and Barrier drapes are not the cheapest options on the GPO contract. But when a surgical-site infection adds $20,000 to a case, the cheap option isn't cheap anymore.
Early detection doesn't eliminate treatment. It reduces its scale. That's exactly how I think about surgical barriers. A drape that prevents fluid strike-through is not about comfort; it's about keeping a contaminant from ever reaching the site. Once you see prevention in those terms, the procurement decision changes. You stop comparing shelf prices and start comparing worst-case outcomes.
What About the Budget? The Objection I Hear Most
I can already hear the finance director: “That's great, but we don't have room in this year's budget for premium prevention products.” I've said that sentence myself. More than once. When I operated by unit price, prevention always lost, because prevention is a future cost and the budget is a present one.
But here's the thing: you already have a prevention budget. You're just spending it after the fact. You're paying for the extra hospital day, the revision surgery, the unplanned maintenance call, the wound that didn't heal on schedule. The only question is whether you pay upstream or downstream. Paying upstream feels harder because it requires a decision before the problem exists. Paying downstream is easier to justify because it's already in the P&L. But it's also a lot more expensive.
I don't buy every premium product. I evaluate each one with the same TCO spreadsheet I would use for a patient lift or a dental implant. Sometimes the premium product doesn't justify itself. But I've stopped dismissing it before running the numbers. And I've added a checklist for every supplier review: published evidence, clinical support, contamination risk, compatibility with existing products, and the cost of failure. That checklist is the cheapest insurance I have.
Five minutes of verification beats five days of correction. That's not a slogan. It's a lesson from every product that failed on my watch.
Bottom Line
Prevention over cure has a reputation for being soft. It's not. It's just good accounting. The most expensive product isn't the one with the higher shelf price. It's the one that fails after you've committed to it.
That's why I now start every procurement conversation with a simple question: What will this cost us in year three? For patient lifts, for dental implant kits, for Mölnlycke dressings, for everything. The answer is usually where the real savings live. The brand that documents its outcomes, publishes its evidence, and charges a fair price for prevention isn't the problem. The problem is pretending prevention is free.
